{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:24:20Z","timestamp":1790436260869,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3404000"],"award-info":[{"award-number":["2023YFC3404000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371781"],"award-info":[{"award-number":["82371781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073752"],"award-info":[{"award-number":["82073752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijbiomac.2025.148726","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T17:16:14Z","timestamp":1762190174000},"page":"148726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress"],"prefix":"10.1016","volume":"332","author":[{"given":"Yuanzhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaicheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingpai","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.148726_bb0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075179","article-title":"Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention","volume":"383","author":"Romero-Gomez","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0025","doi-asserted-by":"crossref","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.metabol.2014.11.009","article-title":"The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy","volume":"64","author":"Liu","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.28697","article-title":"Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients","volume":"65","author":"Leung","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0045","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101115","article-title":"Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in MAFLD","volume":"50","author":"Mashek","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0055","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on MAFLD: Focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0060","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0065","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","article-title":"Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo","volume":"278","author":"Ono","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0070","doi-asserted-by":"crossref","first-page":"E1266","DOI":"10.1210\/jc.2012-1298","article-title":"Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization","volume":"97","author":"Minicocci","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12951-022-01456-z","article-title":"A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease","volume":"20","author":"Hu","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0080","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0085","first-page":"51","article-title":"Efficacy and Safety of Fibroblast Growth Factor 21 Analogues for Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"81","author":"Dolovitsch de Oliveira","year":"2025","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.celrep.2016.08.086","article-title":"mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes","volume":"17","author":"Minard","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0095","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jconrel.2020.05.036","article-title":"Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects","volume":"324","author":"Watanabe","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0105","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0115","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0120","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.3390\/ijms26062672","article-title":"A Novel Recombinant Human FGF21 Analog with High Glycosylation Has a Prolonged Half-Life and Affects Glycemic and Body Weight Control","volume":"26","author":"Du","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0125","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/bph.15725","article-title":"Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats","volume":"179","author":"Tillman","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0135","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward beta-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/jpet.113.204420","article-title":"Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody","volume":"346","author":"Huang","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0145","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/bph.15725","article-title":"Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats","volume":"179","author":"Tillman","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0150","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2016.01.016","article-title":"Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid","volume":"64","author":"Ijssennagger","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154351","article-title":"Ban-xia-xie-xin-tang ameliorates hepatic steatosis by regulating Cidea and Cidec expression in HFD-fed mice","volume":"105","author":"Xia","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0160","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jconrel.2024.11.006","article-title":"Lipidation-dimerization platform unlocks treatment potential of fibroblast growth factor 21 for non-alcoholic steatohepatitis","volume":"376","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0165","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0170","article-title":"Oxidative stress and pro-inflammatory status in patients with non-alcoholic fatty liver disease","volume":"9","author":"Monserrat-Mesquita","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0175","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0180","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0185","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cvr\/cvad095","article-title":"Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options","volume":"119","author":"Grander","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0190","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4254\/wjh.v12.i8.436","article-title":"Lipidomics in non-alcoholic fatty liver disease","volume":"12","author":"Kartsoli","year":"2020","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s13340-024-00760-3","article-title":"High levels of serum dihomo-\u03b3-linolenic acid are associated with non-alcoholic fatty liver disease in type 2 diabetic patients","volume":"16","author":"Mochizuki","year":"2024","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijbiomac.2025.148726_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jceh.2021.08.017","article-title":"Shalimar, A Current Understanding of Bile Acids in Chronic Liver Disease","volume":"12","author":"Farooqui","year":"2022","journal-title":"J. Clin. Exp. Hepatol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025092839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025092839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:01:26Z","timestamp":1767211286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025092839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S0141813025092839"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148726","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.148726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"148726"}}